What 19 Product Launches Taught Me: A Field Guide to Commercial Viability
The product is not the hardest part of a product launch.
That statement surprises people who have not stood inside a launch — inside the field, inside a hospital system, inside the moment a specialist physician decides whether something new is worth changing the way they practice. From the outside, the product looks like the thing. The molecule, the device, the diagnostic, the biologic — the years of science and development that made it real. From the inside, the product is the starting point. What comes after is where most launches are won or lost.
Nineteen product launches across five therapy sectors — pain management, neuromodulation, autoimmune diagnostics, oral specialty therapy, and biologics — taught me a version of this lesson nineteen times, from nineteen different angles, against nineteen different market realities. Each sector had its own stakeholder architecture, its own channel dynamics, its own payer logic, its own physician behavior patterns. Each launch required building the commercial case from the ground up.
What those nineteen launches taught me, distilled: commercial success is not a function of product quality. It is a function of how well an organization understands, reaches, and creates value for every stakeholder in the adoption ecosystem — before any competitor does, and before the market has decided who wins.
Commercial success is not a function of product quality. It is a function of how well an organization understands every stakeholder in the adoption ecosystem — before any competitor does.
Start With the Need, Not the Product
The foundational principle of effective commercialization is not a marketing concept — it is a design principle, and it precedes strategy by years. Organizations that build commercial ecosystems around the needs of their buyers — physicians, patients, payers, and systems — consistently outperform organizations that build commercial ecosystems around the product they have developed and then ask the market to accept it.
This is the marketing concept in its most practical form: the firm exists to identify and satisfy consumer needs profitably. Not to create products and then find consumers for them. In life sciences, this distinction is operationally consequential. A molecule that was developed without patient insight embedded in its trial design, without payer logic embedded in its value proposition, and without prescriber behavior embedded in its communication strategy is not a commercial product. It is a scientific achievement that the market must be convinced to adopt — a fundamentally harder task than the one it should have been.
The first lesson nineteen launches teach is this: the commercial work begins at the point where the need is first identified and the product design begins, not at the point where the product is approved. Organizations that understand this have a structural advantage that compounds across every subsequent phase of development.
The Stakeholder Landscape Is More Complex Than It Appears
In most industries, the customer is the person who buys the product. In life sciences, the customer is a network. The prescribing physician evaluates the clinical evidence. The patient experiences the outcome. The payer determines access and reimbursement. The hospital system or integrated delivery network controls formulary placement. The Key Opinion Leader shapes peer adoption. The pharmacist, the laboratory, the specialty distributor — each plays a role in whether a product reaches the patient who needs it and at what price.
Understanding this network requires more than intuition. It requires systematic segmentation — the process of dividing a heterogeneous market into homogeneous groups whose members share similar needs, behaviors, and decision-making processes. The five criteria that determine whether a market segment is worth pursuing are deceptively simple: is it measurable, substantial, accessible, differentiable, and actionable? In practice, applying those five criteria to the layered stakeholder landscape of US healthcare is one of the most analytically demanding exercises in commercial strategy.
Nineteen launches across five therapy sectors revealed a consistent pattern: the organizations that over-invested in understanding their stakeholder segments before launch — their geographic clustering, their behavioral drivers, their psychographic profiles, their economic incentives — outperformed their competitors at launch and retained that advantage through the product's lifecycle. The organizations that treated segmentation as a retrospective exercise, defining their targets after the commercial infrastructure was already built, spent the product's early commercial life correcting course rather than compounding advantage.
This is covered in depth in the second post in this series. Post 2 — Know Your Customer Better Than They Know Themselves
Positioning Is the Decision That Determines Everything Downstream
Positioning is the distinct image a product occupies in the minds of its target customers — defined relative to every alternative those customers have access to. It is not a tagline. It is not a visual identity. It is the answer to a specific strategic question: given what this product delivers, for whom does it deliver it better than any existing alternative, and why?
In the oral specialty therapy launch I was part of — a product that displaced entrenched biologic therapies through superior branding and marketing rather than superiority of mechanism — the positioning decision was the commercial achievement. The product was not the first in its category. It was not the most potent. What it was, was positioned with precision around the specific patient population and physician concern that the dominant biologics had left underserved. That positioning decision, executed with discipline across every commercial lever — sales force messaging, KOL strategy, payer value proposition, patient communication — drove adoption that market analysts had not anticipated and contributed to the largest pharmaceutical acquisition in history at the time of the transaction, valued at $74 billion.
Positioning requires three things: a clearly defined customer, a set of points of parity that establish competitive relevance, and points of differentiation that are meaningful to that customer and not associated with any competitor. Getting all three right simultaneously is the work. Most organizations get one or two.
The second post in this series goes deep on segmentation, targeting, and positioning as an integrated framework. Post 2 — Know Your Customer Better Than They Know Themselves
Price Is the Strategy, Not the Output
Pricing in life sciences is not a financial exercise that happens after the commercial strategy is set. It is a strategic decision that shapes everything from trial design to market access architecture to long-term brand positioning. Get it wrong — in either direction — and no amount of execution excellence recovers the ground lost.
The framework that clarifies pricing most usefully is the relationship between three values: the True Economic Value (TEV) of the product to a fully informed customer, the customer's perceived value of the product based on available information, and the cost of goods sold. A price set between perceived value and cost of goods creates value for the customer and captures a portion of that value for the organization. A price set above perceived value — regardless of its relationship to true economic value — produces adoption resistance that compounds over time into a market access problem.
In the pain management sector, the neuromodulation sector, and the diagnostics sector across my launch experience, the most common commercial failure mode was not a flawed product — it was a pricing strategy that failed to account for the gap between what the product was worth to a fully informed customer and what the market could actually perceive that value to be at launch. Closing that gap — through medical affairs education, payer evidence generation, health economics modeling, and market access strategy — is as much a commercial discipline as it is a scientific one.
The neuromodulation platform I was part of was subsequently acquired for $25 billion — a figure that reflects not just the technology but the commercial infrastructure built around it. The diagnostics platform filed twice for a Nasdaq IPO before successfully completing its public offering, with a valuation that reflected the market's confidence in the commercial model as much as the diagnostic technology.
The pricing post in this series covers all five pricing strategies, True Economic Value, price sensitivity factors, and the specific dynamics of buy-and-bill versus pharmacy versus laboratory channel distribution in US healthcare. Post 3 — The Price Is the Strategy
Getting Through the Noise Requires a Framework, Not a Budget
A product that is correctly positioned and appropriately priced still fails commercially if the right message does not reach the right stakeholder at the right moment in their decision-making process. In a market where every prescriber, payer, and patient is bombarded daily by competing claims — and where digital media, social platforms, and AI-driven content have compressed the signal-to-noise ratio to near zero — the question is not how loudly to communicate but how precisely.
The 6M's framework provides the organizing structure: Market (who), Motive (why they buy), Message (what to say), Media (where to say it), Money (how much to spend), and Measurement (how to know if it worked). Every element must be aligned. A powerful message delivered through the wrong medium to the wrong market segment produces noise, not adoption. A correctly targeted campaign with a poorly defined motive wastes the reach it earns.
The three communication motives — Inform, Persuade, and Remind — map directly onto the consumer decision-making process: awareness, evaluation, and loyalty. In life sciences, these three stages look different than they do in consumer goods. A physician's awareness stage may span years of scientific exchange through medical affairs. The evaluation stage involves clinical evidence, peer conversation, and trial experience. The loyalty stage — retention and advocacy — is built through outcomes data and the quality of the ongoing relationship between the organization and the prescriber community.
What nineteen launches demonstrated consistently: organizations that invested in measurement from day one — that defined their KPIs before the campaign launched and tracked them with the same rigor they applied to clinical endpoints — adapted faster, corrected earlier, and compounded commercial momentum more effectively than those that measured retrospectively.
The communication post in this series covers the 6M's in detail, the shift from unidirectional to bidirectional to social communication, media effectiveness by stage, and how to build a measurement architecture that delivers accountability. Post 4 — Getting Through the Noise
Market Access Is the Variable Nobody Fully Prepares For
The US healthcare system is the most complex commercial channel in the world. It is not one market — it is a layered system of payers, formularies, benefit designs, channel economics, and regulatory requirements that varies by geography, by product category, by indication, and by the specific buying center involved in each transaction. A product that is approved, priced, positioned, and communicated correctly can still fail commercially if its market access strategy fails to account for how a dollar actually flows through the system to reach the patient.
Buy-and-bill products — those administered in a physician's office or hospital and billed directly to the payer — operate under a completely different economic logic than products distributed through specialty pharmacy or through clinical laboratory channels. Across pain management, neuromodulation, autoimmune diagnostics, and biologics, each sector operated under a different channel architecture with different economic incentives, different payer relationships, and different compliance requirements.
Understanding that architecture — deeply, operationally, before launch — is not a market access team function. It is a commercial strategy function that must be integrated into positioning, pricing, and communication strategy from the earliest development stages. The organizations that treated market access as a post-approval problem consistently underperformed those that built their commercial model around the market access reality from the beginning.
The market access post in this series covers the US healthcare system's dollar flow, the specific dynamics of each channel distribution pathway, managed care strategy, and the relationship between health economics evidence and payer decision-making. Post 5 — Market Access as a Commercial Strategy Discipline
What the Field Actually Teaches
Nineteen product launches across five therapy sectors — three of which were part of transactions totaling over $100 billion in acquirer-stated value, and one of which completed a Nasdaq public offering — produced a body of field experience that business school frameworks illuminate but cannot replace.
What the field teaches, with a specificity that no case study fully captures: the commercial ecosystem is more complex, more human, and more interconnected than any single framework accounts for. The stakeholders are real people with real constraints. The payers have real actuarial pressures. The physicians have real practice economics. The patients have real lived experiences of the conditions these products treat.
The frameworks in this series — segmentation and positioning, pricing strategy, communication architecture, market access design — are not academic constructs. They are the analytical tools that let an organization see that complexity clearly enough to act on it with precision. Used well, they turn the commercial ecosystem from a source of uncertainty into a source of advantage.
Used poorly — applied after the product is approved, without the stakeholder intelligence to make them specific, without the measurement architecture to make them accountable — they produce activity without momentum.
The difference between the two is what nineteen launches actually teach. The posts in this series go deep on each framework. The field is where they come alive.
The frameworks are the tools. The field is where they come alive. The difference between using them well and using them poorly is what nineteen launches actually teach.
About This Series
This is the anchor post for a five-part series on life sciences commercialization strategy. Each post goes deep on one framework cluster from the field experience behind nineteen product launches across five therapy sectors.
Post 1: "What 19 Product Launches Taught Me: A Field Guide to Commercial Viability" — You are here — the meta-argument and landscape overview.
Post 2: "Know Your Customer Better Than They Know Themselves" — Segmentation, targeting, positioning, points of parity and differentiation, and perceptual mapping in life sciences.
Post 3: "The Price Is the Strategy" — True Economic Value, perceived value, cost of goods sold, five pricing strategies, price sensitivity, and channel economics in US healthcare.
Post 4: "Getting Through the Noise" — The 6M's communication framework, three motives (Inform, Persuade, Remind), media effectiveness by stage, bidirectional digital communication, KPI architecture.
Post 5: "Market Access as a Commercial Strategy Discipline" — The US healthcare system's dollar flow, channel distribution pathways, managed care strategy, and health economics evidence.
